Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2007

01-10-2007

Association between nitric oxide levels on myocardial injury in non-ST elevation acute coronary syndromes

Authors: Mustafa Yazici, Sabri Demircan, Kenan Durna

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2007

Login to get access

Abstract

Background

Impairment of the release of endothelium and platelet derived-nitric oxide (NO) increases thrombus formation that is rich in platelets in non-ST elevation acute coronary syndromes (NSTE-ACS). Since intracoronary thrombus formation and distal embolization increases risk of myocardial injury, we studied the relationship between NO levels and Tn-I in patients with NSTE-ACS.

Methods

Nitric oxide and Tn-I levels of 234 consecutive patients with NSTE-ACS were measured from venous samples at admission. The 137 patients whose Tn-I levels were below 0.20 ng/ml grouped as Tn-I negative and 97 patients whose Tn-I levels were equal to and above 0.21 ng/ml were grouped as Tn-I positive. Presence of visible thrombus, degree of flow in Thrombolysis in Myocardial Infarction (TIMI), and morphology of the lesion were evaluated with coronary angiographies.

Results

Presence of coronary thrombus, impaired TIMI flow, frequency of complex lesions, angina and ST-T changes were more frequent and associated with Tn-I levels in Tn-I positive patients. NO levels were lower in patients who were Tn-I positive, had angina and ST-T changes. NO levels were similar between patients with simple or complex lesions, but lower in patients who had coronary thrombus or TIMI flow grade <2. There was a negative correlation between levels of Tn-I and NO (r = −0.87, P < 0.001). Logistic regression analysis revealed that NO levels were independent predictors in the differentiation of Tn-I negatives and positives (r = 0.527, P < 0.001).

Conclusion

This study revealed that NO levels are associated with myocardial injury in patients with NSTE-ACS.
Literature
1.
go back to reference Hamm CW, Ravkilde J, Gerhardt W et al (1992) The prognostic value of serum troponin T in unstable angina. N Engl J Med 327:146–150PubMedCrossRef Hamm CW, Ravkilde J, Gerhardt W et al (1992) The prognostic value of serum troponin T in unstable angina. N Engl J Med 327:146–150PubMedCrossRef
2.
go back to reference Antman EM, Tanasijevic MJ, Thompson B et al (1996) Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335:1342–1349PubMedCrossRef Antman EM, Tanasijevic MJ, Thompson B et al (1996) Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335:1342–1349PubMedCrossRef
3.
go back to reference Benamer H, Steg PG, Benessiano J et al (1999) Elevated cardiac troponin I predicts a high risk angiographic anatomy of the culprit lesion in unstable angina. Am Heart J 137:815–820PubMedCrossRef Benamer H, Steg PG, Benessiano J et al (1999) Elevated cardiac troponin I predicts a high risk angiographic anatomy of the culprit lesion in unstable angina. Am Heart J 137:815–820PubMedCrossRef
4.
go back to reference Okamatsu K, Takano M, Sakai S et al (2004) Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation 109:465–470PubMedCrossRef Okamatsu K, Takano M, Sakai S et al (2004) Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation 109:465–470PubMedCrossRef
5.
go back to reference Hamm CW, Braunwald E (2000) A classification of unstable angina revisited. Circulation 102:118–122PubMed Hamm CW, Braunwald E (2000) A classification of unstable angina revisited. Circulation 102:118–122PubMed
6.
go back to reference Topol EJ, Yadav JS (2000) Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101:570–580PubMed Topol EJ, Yadav JS (2000) Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101:570–580PubMed
7.
go back to reference Vane JR, Anggard EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36PubMedCrossRef Vane JR, Anggard EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36PubMedCrossRef
8.
go back to reference Keh D, Thieme A, Kurer I, Falke KJ, Gerlach H (2003) Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine. Blood Coagul Fibrinolysis 14:327–334PubMedCrossRef Keh D, Thieme A, Kurer I, Falke KJ, Gerlach H (2003) Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine. Blood Coagul Fibrinolysis 14:327–334PubMedCrossRef
9.
go back to reference Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, Vita JA (1998) Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98:1481–1486PubMed Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, Vita JA (1998) Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98:1481–1486PubMed
10.
go back to reference Diodati JG, Dakak N, Gilligan DM, Quyyumi AA (1998) Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98:17–24PubMed Diodati JG, Dakak N, Gilligan DM, Quyyumi AA (1998) Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98:17–24PubMed
11.
go back to reference Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and (15N) nitrate in biological fluids. Anal Biochem 126:131–138PubMedCrossRef Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and (15N) nitrate in biological fluids. Anal Biochem 126:131–138PubMedCrossRef
13.
go back to reference Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L; FRISC II (Fast Revascularization during InStability in CAD) Investigators (2001) Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 38:979–986 Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L; FRISC II (Fast Revascularization during InStability in CAD) Investigators (2001) Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 38:979–986
14.
go back to reference Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML (1999) Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 100:1509–1514PubMed Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML (1999) Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 100:1509–1514PubMed
15.
go back to reference Lehrke S, Giannitsis E, Katus HA (2004) Admission troponin T, advanced age and male gender identify patients with improved myocardial tissue perfusion after abciximab administration for ST-segment elevation myocardial infarction. Thromb Haemost 92:1214–1220PubMed Lehrke S, Giannitsis E, Katus HA (2004) Admission troponin T, advanced age and male gender identify patients with improved myocardial tissue perfusion after abciximab administration for ST-segment elevation myocardial infarction. Thromb Haemost 92:1214–1220PubMed
16.
go back to reference Hamm CW, Heeschen C, Goldmann B et al (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators, N Engl J Med 340:1623–1629PubMedCrossRef Hamm CW, Heeschen C, Goldmann B et al (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators, N Engl J Med 340:1623–1629PubMedCrossRef
17.
go back to reference Newby LK, Ohman EM, Christenson RH et al (2001) Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy. Circulation 103:2891–2896PubMed Newby LK, Ohman EM, Christenson RH et al (2001) Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy. Circulation 103:2891–2896PubMed
18.
go back to reference Corseaux D, Ollivier V, Fontaine V et al (2002) Hemostasis imbalance in experimental hypertension. Mol Med 8:169–178PubMed Corseaux D, Ollivier V, Fontaine V et al (2002) Hemostasis imbalance in experimental hypertension. Mol Med 8:169–178PubMed
19.
go back to reference Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD (2005) Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol 25:2661–2666PubMedCrossRef Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD (2005) Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol 25:2661–2666PubMedCrossRef
20.
go back to reference Stoupakis G, Orlando J, Kalia H, Skurnick J, Saric M, Arora R (2003) Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide. J Invasive Cardiol 15:476–480PubMed Stoupakis G, Orlando J, Kalia H, Skurnick J, Saric M, Arora R (2003) Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide. J Invasive Cardiol 15:476–480PubMed
21.
go back to reference Davani S, Yan Y, Bouhaddi M et al (2002) Effects of nitric oxide on cardioprotection prior to ischemia-reperfusion. Therapie 57:157–162PubMed Davani S, Yan Y, Bouhaddi M et al (2002) Effects of nitric oxide on cardioprotection prior to ischemia-reperfusion. Therapie 57:157–162PubMed
22.
go back to reference Pinelli A, Trivulzio S, Tomasoni L, Bertolini B, Brenna S, Bonacina E (2002) Cardiac necrosis markers associated with low nitric oxide levels in the plasma of rabbits after treatment with vasopressin: protective effects of nitroglycerin administration. Pharmacol Res 45:427–434PubMedCrossRef Pinelli A, Trivulzio S, Tomasoni L, Bertolini B, Brenna S, Bonacina E (2002) Cardiac necrosis markers associated with low nitric oxide levels in the plasma of rabbits after treatment with vasopressin: protective effects of nitroglycerin administration. Pharmacol Res 45:427–434PubMedCrossRef
23.
go back to reference Kita Y, Ozaki R, Sakai S et al (1994) Antianginal effects of FK409, a new spontaneous NO releaser. Br J Pharmacol 113:1137–1140PubMed Kita Y, Ozaki R, Sakai S et al (1994) Antianginal effects of FK409, a new spontaneous NO releaser. Br J Pharmacol 113:1137–1140PubMed
24.
go back to reference Ishii H, Ichimiya S, Kanashiro M et al (2005) Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 112:1284–1288PubMedCrossRef Ishii H, Ichimiya S, Kanashiro M et al (2005) Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 112:1284–1288PubMedCrossRef
Metadata
Title
Association between nitric oxide levels on myocardial injury in non-ST elevation acute coronary syndromes
Authors
Mustafa Yazici
Sabri Demircan
Kenan Durna
Publication date
01-10-2007
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2007
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0039-3

Other articles of this Issue 2/2007

Journal of Thrombosis and Thrombolysis 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine